The chemical giant’s push to float its crop-science division is no longer a distant ambition but a logistics exercise in the truest sense. As BASF races to complete the legal and operational separation of Agricultural Solutions across the Americas and Europe — with Asia slated to follow by the end of 2026 — the company is simultaneously pouring capital into the kind of unglamorous, back-office infrastructure that rarely makes headlines but often determines whether a spin-off lands on time.
The most telling example: a commitment of more than €100 million to expand rail logistics at the Ludwigshafen headquarters, a project backed by €51 million in federal funding. On its face, the investment is about moving freight more efficiently. But it also reads as a deliberate effort to harden the parent company’s own operations ahead of the agribusiness separation, ensuring that whatever remains at the core is lean, resilient, and less exposed to the kind of external shocks that have historically disrupted production.
That last point is not academic. BASF chief executive Markus Kamieth was recently forced to throttle output at certain plants when water levels on the Rhine dropped too low for reliable barge traffic — a recurring vulnerability that the company says had no significant earnings impact, but which underscores how thin the operating margin for error has become during a multi-year restructuring.
The Clock on the Agribusiness IPO
The formal timeline is now taking shape. Livio Tedeschi, the board member overseeing the carve-out, confirmed that the separation of Agricultural Solutions is largely complete in North and South America and Europe. Asia remains the final piece, with completion targeted for the end of 2026. The structural prerequisites for a listing — whether a full spin-off, a partial IPO, or a sale — are expected to be in place by mid-2027, with a market debut that year still the working assumption.
The stakes are considerable. Analysts value the agribusiness unit at between €20 billion and €30 billion, and the division’s research firepower is being quietly upgraded in anticipation of an independent future. A new Climate Center in Limburgerhof, funded with a low double-digit million-euro investment, will consolidate research into climate-resistant active ingredients and global regulatory approval work — an area of growing strategic importance as pesticide registration rules tighten worldwide.
For BASF shareholders, the bull case rests on the idea that a standalone, well-capitalized crop-science company could command a richer valuation than it does buried inside a diversified conglomerate. A clean carve-out would also free up capital for the parent’s broader restructuring or further share buybacks. The second quarter offered a supportive backdrop: EBITDA before special items came in at €2.4 billion, comfortably ahead of consensus, and management lifted its full-year guidance to a range of €6.9 billion to €7.7 billion.
Should investors sell immediately? Or is it worth buying BASF?
Where the Skepticism Creeps In
Yet the bear case is equally straightforward, and it hinges on execution risk. “Keeping an IPO in view” is not a commitment, and the Asia leg of the carve-out remains the least advanced. Any slippage there pushes back the entire 2027 timetable, leaving the market to price an extended period of uncertainty over deal structure and the use of proceeds.
The analyst community is visibly split on how to value the transformation story. The DZ Bank raised its price target to €64 in late July while reaffirming a buy recommendation. Berenberg, in the same window, cut its target to €47 with a hold rating. That divergence suggests the market has yet to reach a verdict on whether the carve-out is a value-creation event or a prolonged distraction.
Meanwhile, the company is not idling on the commercial front. Price increases are being pushed through across several specialty chemical lines: neopentyl glycol under the NEOL brand in the US and Canada, effective September 1, and earlier announcements covering caprolactam, polyamide 6, and copolyamide in North America at $0.08 per pound, also effective from the start of September. New capacity is coming online elsewhere — a global performance laboratory for superabsorbents and diapers opened in Mumbai, and a new generation of floral active ingredients under the Floragenist brand, built on epigenetic research and the AquaGenesis extraction technology, was unveiled in the personal care segment.
A Market That’s Watching, Not Waving
The share price reaction to all of this activity has been muted. The stock closed Thursday at €51.25, down 1.0 percent on the day, though the longer-term picture is more constructive: a 4.6 percent gain over 30 days, a 15 percent advance since the start of the year, and a current level about 4.2 percent above the 50-day moving average. The 52-week high of €55.05, set in April, sits 6.9 percent above the current price.
The next milestone for investors is the third-quarter earnings call on October 28, where management is expected to provide fresh detail on both the carve-out progress and the full-year guidance. Between now and then, the market will be weighing whether the company’s parallel tracks — infrastructure hardening, price discipline, and the agribusiness separation — are converging into a coherent whole or pulling in different directions. The answer, as with most multi-year transformations, will only become clear in the execution.
Ad
BASF Stock: Buy or Sell?! New BASF Analysis from August 21 delivers the answer:
The latest BASF figures speak for themselves: Urgent action needed for BASF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 21.
BASF: Buy or sell? Read more here...
